Ramirez A, Van Der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, Popp J, Lacour A, Drichel D, Louwersheimer E, Kummer MP, Cruchaga C, Hoffmann P, Teunissen C, Holstege H, Kornhuber J, Peters O, Naj AC, Chouraki V, Bellenguez C, Gerrish A, Heun R, Froelich L, Huell M, Buscemi L, Herms S, Koelsch H, Scheltens P, Breteler MM, Ruether E, Wiltfang J, Goate A, Jessen F, Maier W, Heneka MT, Becker T, Noethen MM (2014)
Publication Type: Journal article
Publication year: 2014
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option B
Book Volume: 23
Pages Range: 6644-58
Journal Issue: 24
DOI: 10.1093/hmg/ddu372
Cerebrospinal fluid amyloid-beta 1-42 (A?1-42) and phosphorylated Tau at position 181 (pTau181) are biomarkers of Alzheimer's disease (AD). We performed an analysis and meta-analysis of genome-wide association study data on A?1-42 and pTau181 in AD dementia patients followed by independent replication. An association was found between A?1-42 level and a single-nucleotide polymorphism in SUCLG2 (rs62256378) (P = 2.5×10(-12)). An interaction between APOE genotype and rs62256378 was detected (P = 9.5 × 10(-5)), with the strongest effect being observed in APOE-?4 noncarriers. Clinically, rs62256378 was associated with rate of cognitive decline in AD dementia patients (P = 3.1 × 10(-3)). Functional microglia experiments showed that SUCLG2 was involved in clearance of A?1-42.
APA:
Ramirez, A., Van Der Flier, W.M., Herold, C., Ramonet, D., Heilmann, S., Lewczuk, P.,... Noethen, M.M. (2014). SUCLG2 identified as both a determinator of CSF A?1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 23(24), 6644-58. https://doi.org/10.1093/hmg/ddu372
MLA:
Ramirez, Alfredo, et al. "SUCLG2 identified as both a determinator of CSF A?1-42 levels and an attenuator of cognitive decline in Alzheimer's disease." Human Molecular Genetics 23.24 (2014): 6644-58.
BibTeX: Download